Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today reported its financial results for the three and twelve months ended December 31, 2025.
Corporate Highlights
- Announced Positive Results from PRIME Clinical Study in late-stage chronic kidney disease patients
- Announced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injury
- Received net proceeds of $6.7 million from warrant inducement in January 2026
- Clinical data on the potential therapeutic benefit of Gemini for the treatment of acute kidney injury (AKI) and chronic kidney disease (CKD) will be presented at the International Conference on Advances in Critical Care Nephrology in San Diego (March 29 - April 1, 2026)
"2025 was a positive year for Revelation with significant advancement of the Gemini program," said James Rolke, Chief Executive Officer of Revelation. "We look forward to building on this momentum in 2026 to expeditiously bring Gemini to patients in need and adding to shareholder value."
Results of Operations
As of December 31, 2025, Revelation had $10.7 million in cash and cash equivalents, compared to $6.5 million as of December 31, 2024. The increase in cash and cash equivalents was primarily due to net cash proceeds from the May 2025 public offering and the September 2025 warrant inducement, offset by cash used for operating activities. Based on current operating plans and projections, Revelation believes its current cash and cash equivalents are sufficient to fund operations into the first quarter of 2027.
Net cash used for operating activities for the twelve months ended December 31, 2025 was $8.3 million compared to net cash used for operating activities of $18.3 million for the same period in 2024. Net loss for the three months ended December 31, 2025 was $2.5 million, or $(1.65) basic and diluted net loss per share, compared to a net loss of $1.7 million, or $(59.76) basic and diluted net loss per share for the same period in 2024. Net loss for the year ended December 31, 2025 was $8.9 million, or $(23.95) basic and diluted net loss per share compared to net loss of $15.0 million, or $(1,052.16) basic and diluted net loss per share for the year ended December 31, 2024.
About Gemini
Gemini is the Company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response and has been demonstrated to have the potential to treat acute and chronic diseases associated with dysregulated inflammation. Gemini is currently being evaluated as a potential treatment for acute kidney injury (GEM-AKI); Gemini is also being developed as a treatment for chronic kidney disease (GEM-CKD), as a treatment to reduce hyperinflammation and infection associated with severe burn (GEM-PBI), and as a treatment to prevent post-surgical infection (GEM-PSI). The potential of Gemini to correct dysregulated inflammation has been demonstrated in multiple preclinical models of AKI, CKD, and infection, as well as in two phase 1 clinical studies. See additional detail here.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment of chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.
For more information, please visit www.RevBiosciences.com.
Three Months Ended December 31,
Year Ended December 31,
2025
2024
2025
2024
Operating expenses:
Research and development
$
964,189
$
605,504
$
4,063,857
$
3,548,996
General and administrative
1,607,398
1,148,384
5,006,957
4,426,113
Total operating expenses
2,571,587
1,753,888
9,070,814
7,975,109
Loss from operations
(2,571,587
)
(1,753,888
)
(9,070,814
)
(7,975,109
)
Other income (expense):
Change in fair value of warrant liability
87
2,557
2,158
81,441
Other income (expense), net
60,493
25,612
155,007
(7,144,868
)
Total other income (expense), net
60,580
28,169
157,165
(7,063,427
)
Net loss
$
(2,511,007
)
$
(1,725,719
)
$
(8,913,649
)
$
(15,038,536
)
Deemed dividends
(5,951,528
)
Net loss attributable to common stockholders
(2,511,007
)
(1,725,719
)
(14,865,177
)
(15,038,536
)
Net loss per share, basic and diluted
$
(1.65
)
$
(59.76
)
$
(23.95
)
$
(1,052.16
)
Weighted-average shares used to compute net loss per share, basic and diluted
1,524,011
28,876
620,785
14,293
REVELATION BIOSCIENCES, INC.
Consolidated Balance Sheets
December 31, 2025
December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents
$
10,700,331
$
6,499,018
Prepaid expenses and other current assets
111,297
66,699
Total current assets
10,811,628
6,565,717
Property and equipment, net
18,067
56,332
Operating lease right-of-use asset
722,288
Other assets
30,941
Total assets
$
11,582,924
$
6,622,049
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$
577,501
$
783,621
Accrued expenses
1,397,644
1,130,046
Operating lease liability
23,013
Total current liabilities
1,998,158
1,913,667
Operating lease liability, net of current portion
723,771
Total liabilities
2,721,929
1,913,667
Commitments and Contingencies (Note 4)
Stockholders' equity:
Common Stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024 and 1,583,969 and 43,526 issued and outstanding at December 31, 2025 and December 31, 2024, respectively
1,584
44
Additional paid-in-capital
58,278,698
45,213,976
Accumulated deficit
(49,419,287
)
(40,505,638
)
Total stockholders' equity
8,860,995
4,708,382
Total liabilities and stockholders' equity
$
11,582,924
$
6,622,049
Company Contacts
Mike Porter Investor Relations Porter LeVay & Rose Inc. Email: [email protected]
Chester Zygmont, III Chief Financial Officer Revelation Biosciences Inc. Email: [email protected]
SOURCE: Revelation Biosciences, Inc.
View the original
press release
on ACCESS Newswire